INT177481

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.31
First Reported 2004
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 6
Total Number 7
Disease Relevance 5.34
Pain Relevance 1.06

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (BBS2) cytoplasm (BBS2)
BBS2 (Homo sapiens)
Pain Link Frequency Relevance Heat
beta blocker 118 100.00 Very High Very High Very High
Inflammation 7 94.92 High High
Angina 5 94.84 High High
cINOD 3 62.24 Quite High
Calcium channel 3 59.88 Quite High
cytokine 1 54.00 Quite High
corticosteroid 2 34.88 Quite Low
acular 3 18.16 Low Low
aspirin 10 5.00 Very Low Very Low Very Low
agonist 10 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Bardet-biedl Syndrome 2 100.00 Very High Very High Very High
Nicotine Addiction 68 99.88 Very High Very High Very High
Heart Rate Under Development 33 99.74 Very High Very High Very High
Hypertension 69 99.58 Very High Very High Very High
Myocardial Infarction 79 99.34 Very High Very High Very High
Hyperlipidemia 12 98.40 Very High Very High Very High
Lung Cancer 6 96.88 Very High Very High Very High
Chronic Disease 2 95.28 Very High Very High Very High
Pneumonia 2 94.92 High High
Cv General 3 Under Development 4 94.84 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
BBs also reduce mortality in the perioperative period.
Negative_regulation (reduce) of BBs associated with beta blocker
1) Confidence 0.31 Published 2007 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2699954 Disease Relevance 1.36 Pain Relevance 0.47
To reduce nitric oxide production, Enkhbaatar and colleagues (2003) examined the use of an iNOS inhibitor, BBS-2, on sheep.
Spec (examined) Negative_regulation (inhibitor) of BBS-2 associated with bardet-biedl syndrome
2) Confidence 0.10 Published 2008 Journal Drug design, development and therapy Section Body Doc Link PMC2761179 Disease Relevance 1.08 Pain Relevance 0.21
Median daily dosages of BBs, ACE/ARBs and statins are presented as DDDs with 95% confidence intervals for age groups and gender in Figure 1.
Negative_regulation (dosages) of BBs associated with beta blocker
3) Confidence 0.08 Published 2010 Journal BMC Public Health Section Body Doc Link PMC2911401 Disease Relevance 0 Pain Relevance 0.21
For now, family physicians should ensure that all eligible patients with a prior MI or a history of CHF are offered BBs or ACE inhibitors.
Negative_regulation (inhibitors) of BBs associated with heart rate under development and myocardial infarction
4) Confidence 0.05 Published 2004 Journal BMC Fam Pract Section Body Doc Link PMC416476 Disease Relevance 0.73 Pain Relevance 0
In addition, expression of EPHX1 was increased in BAL cells of smokers, but decreased in BBs.
Negative_regulation (decreased) of BBs associated with nicotine addiction
5) Confidence 0.04 Published 2006 Journal Environ Health Perspect Section Body Doc Link PMC1665420 Disease Relevance 0.80 Pain Relevance 0
Further research with patients who appear eligible for BBs or ACE inhibitors but are untreated is needed to clarify the reasons for this care gap and suggest strategies to optimize management.
Negative_regulation (inhibitors) of BBs
6) Confidence 0.03 Published 2004 Journal BMC Fam Pract Section Body Doc Link PMC416476 Disease Relevance 0.47 Pain Relevance 0.03
The proportion of essential hypertensive patients prescribed BBs appear to decrease between 1995 and 2000; whereas the proportion of essential hypertensive patients prescribed ARBs appear to increase.
Negative_regulation (decrease) of BBs associated with beta blocker and hypertension
7) Confidence 0.03 Published 2006 Journal Clinical Interventions in Aging Section Body Doc Link PMC2695181 Disease Relevance 0.90 Pain Relevance 0.14

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox